<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00376467</url>
  </required_header>
  <id_info>
    <org_study_id>LAL0201</org_study_id>
    <nct_id>NCT00376467</nct_id>
  </id_info>
  <brief_title>STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia</brief_title>
  <official_title>STI 571 (GLIVEC) in the Treatment of Philadelphia-chromosome Positive and/or BCR/ABL Rearranged Adult Acute Lymphoblastic Leukemia. GIMEMA LAL 0201.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <brief_summary>
    <textblock>
      This proposal, developed in the framework of the GIMEMA, will permit:&#xD;
&#xD;
        -  to evaluate the activity and toxicity of imatinib in the treatment of Ph+ acute&#xD;
           lymphoblastic leukemia;&#xD;
&#xD;
        -  to evaluate the molecular response to the treatment, and to monitor the molecular status&#xD;
           of remission in all cases achieving or not a molecular response.&#xD;
&#xD;
      The GIMEMA has activated a network to centralize all biological samples (bone marrow and&#xD;
      peripheral blood) at diagnosis from all new ALL patients. This will permit to identify, in&#xD;
      particular, Ph + and/or BCR/ABL + cases within 5 days from diagnosis, thus permitting to&#xD;
      treat these patients according to different programs on the basis of the presence of Ph&#xD;
      chromosome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Imatinib shows a specific activity for the ABL protein- tyrosine kinase at the in vitro and&#xD;
      in vivo level. The compound exerts a direct inhibition on the proliferation of BCR/ABL+ve&#xD;
      cells, in cell lines derived from ALL and CML patients, inducing apoptosis. Induction of&#xD;
      apoptosis by imatinib was observed also in primary samples of leukemic cells obtained from&#xD;
      Ph+ve ALL patients. Since activated BCR/ABL tyrosine kinase is present in nearly all patients&#xD;
      with CML and in 25-30% of those with ALL, these two diseases are the ideal targets to verify&#xD;
      the potential therapeutic activity of this ABL specific tyrosine kinase inhibitor. So far&#xD;
      only limited experiences on the therapeutic benefit of imatinib in ALL patients have been&#xD;
      referred. In one of these studies, all 10 treated patients had received prior&#xD;
      chemotherapeutic treatment for their leukemia. Imatinib was administered as daily oral&#xD;
      therapy and all patients were treated on outpatient basis. Different dosages were tested:&#xD;
      300, 400, 500 mg/day for 28 days. Some responding patients showed prolonged myelosuppression,&#xD;
      but only a minority of these required hospitalization, while other side effects appeared&#xD;
      acceptable. Although these results demonstrated that Imatinib, as a single agent, is active&#xD;
      in BCR/ABL +ve ALL, being able to induce a high response rate, however these responses&#xD;
      appeared to be short. This occurred mainly in patients with advanced leukemia, thus it could&#xD;
      be hypothesized that early relapse, in these patients, may due to a pre-existing resistance&#xD;
      or developed resistance to Imatinib. In vitro studies as well as limited preclinical&#xD;
      experiences are showing enhanced antileukemic effects of Imatinib in combination with&#xD;
      cytotoxic drugs, thus further clinical trials should be aimed to ascertain, mainly in&#xD;
      previously untreated patients, which are the optimal dosage and the best duration of&#xD;
      treatment for maximal therapeutic benefit and to test if this agent, combined with&#xD;
      conventional chemotherapy, could really enhance its antileukemic activity.&#xD;
&#xD;
      The Gimema Group will run two distinct studies among the same protocol to verify the&#xD;
      antileukemic activity and safety of imatinib in Ph+ve and/or BCR/ABL +ve ALL:&#xD;
&#xD;
      Study A: Imatinib as post-consolidation therapy in adult (&gt;=18 and &lt;=60 yrs) ALL patients in&#xD;
      1st CHR; Study B: Imatinib without chemotherapy for remission induction in elderly (&gt;60&#xD;
      years) ALL patients.&#xD;
&#xD;
      This proposal, developed in the framework of the GIMEMA, will include:&#xD;
&#xD;
        1. centralization of all biological samples (bone marrow and peripheral blood) at diagnosis&#xD;
           from all new ALL patients, to identify, in particular, Ph + and/or BCR/ABL + cases;&#xD;
&#xD;
        2. evaluation of the molecular response to the treatment, and monitoring the molecular&#xD;
           status during the hematological remission in all cases in CR;&#xD;
&#xD;
        3. treatment of all adult patients with the same induction and consolidation treatment&#xD;
           already used in the past by GIMEMA for Ph+ ALL, to have also the possibility of an&#xD;
           historical control versus patients treated before the &quot;imatinib era&quot;.&#xD;
&#xD;
      Study A: Imatinib in Ph +ve and/or BCR/ABL +ve adult (age &lt;60 years) ALL patients in first&#xD;
      CHR after induction and consolidation treatment.&#xD;
&#xD;
      Aimed to verify the activity and safety of STI 571 administered after the induction and&#xD;
      consolidation therapy in Ph+ve and/or Bcr/Abl+ve ALL patients in 1st CHR (+CMR). A cohort of&#xD;
      38 patients will be enrolled. All Gimema Centers can join this study. Quantitative Rt-PCR&#xD;
      assay is mandatory before start of Imatinib treatment.&#xD;
&#xD;
      Patients will receive on an out-patients basis Imatinib p.o. at the dosage of 400 mg x&#xD;
      2/daily for 6 months. After completing the 6-months therapy, and in absence of safety&#xD;
      concerns, patients may receive additional therapy with Imatinib, provided that, in the&#xD;
      opinion of investigator, the patient has benefited from treatment.&#xD;
&#xD;
      Study B: Imatinib as induction treatment in newly diagnosed Ph+ and/or Bcr/Abl+ elderly (age&#xD;
      &gt;60 years) ALL patients.&#xD;
&#xD;
      Aimed to verify the activity and safety of Imatinib combined with steroids during the&#xD;
      induction phase in elderly (&gt;60 years) Ph+ve and/or Bcr/Abl+ve ALL patients. A cohort of 53&#xD;
      patients will be enrolled. All Gimema Centers can join this study. The cytogenetic and/or&#xD;
      molecular diagnosis must be obtained within 5 days from diagnosis.&#xD;
&#xD;
      Patients will receive Imatinib p.o at the dosage of 400 mg x 2/daily for 30 days on an&#xD;
      out-patients basis. After completing induction therapy patients may receive additional&#xD;
      therapy with Imatinib, provided that, in the opinion of investigator, the patient benefited&#xD;
      from treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>for Study A, the primary endpoint for activity is overall CMR rate</measure>
    <time_frame>after 6 months of imatinib treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>for Study B, the primary endpoint for activity is overall CHR (+/- CMR) rate .</measure>
    <time_frame>after induction treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete hematological or molecular remission duration</measure>
    <time_frame>at study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival.</measure>
    <time_frame>at study end</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">105</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with Ph +ve and/or BCR/ABL +ve ALL, either in 1st CHR (independently from the&#xD;
             molecular status) for study A, or at diagnosis and untreated for study B;&#xD;
&#xD;
          -  Age &gt;18 years and &lt;60 for study A, &gt;60 for study B;&#xD;
&#xD;
          -  Written voluntary informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients of childbearing potential without a negative pregnancy test prior to the&#xD;
             initiation of study. Barrier contraceptive precautions are to be used throughout the&#xD;
             trial in both sexes;&#xD;
&#xD;
          -  Pretreatment with steroids for more than 10 days in study B;&#xD;
&#xD;
          -  Serum bilirubin and creatinine values &gt;3 the upper limit of normal range;&#xD;
&#xD;
          -  SGOT and SGPT values &gt;3 the upper limit of the normal range;&#xD;
&#xD;
          -  Patients who had received any other investigational agent within 4 weeks before the&#xD;
             enrollment;&#xD;
&#xD;
          -  Patients with cardiovascular diseases grade &gt;3 according to the New York Heart&#xD;
             Association (see Appendix 1);&#xD;
&#xD;
          -  Patients with a history of non compliance to medical regimen or who are considered&#xD;
             potentially unreliable;&#xD;
&#xD;
          -  Patients with moderate/severe mood or psychiatric disorders;&#xD;
&#xD;
          -  Concomitant neoplasia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Baccarani</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università degli Studi di Udine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Nuovo Ospedale &quot;Torrette&quot;</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az.Ospedaliera S.G.Moscati</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia &quot;Lorenzo e A. Seragnoli&quot; - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale A. Perrino</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Catania - Cattedra di Ematologia - Ospedale &quot;Ferrarotto&quot;</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedaliera Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - Unità Operativa di Ematologia</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Arcispedale Sant'Anna Dipartimento di Scienze Mediche Sezione di Ematologia e Fisiopatologia dell'Emostasi</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda &quot; Ca Granda&quot;</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Modenese - Dipartimento di Oncoematologi</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria - Università degli Studi di Napoli &quot;Federico II&quot; - Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servizio Sanitario Nazionale - Azienda Ospedaliera di Rilievo Nazionale &quot;A. Cardarelli&quot; - Struttura Complessa di Ematologia - Div. TERE- 4° piano - Padiglione Palermo</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>zienda Ospedaliera di Rilievo Nazionale &quot;A. Cardarelli&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Oncoematologia di Nocera Inferiore-plesso ospedaliero &quot;A. Tortora&quot; di Pagani del DEA Nocera-Pagani</name>
      <address>
        <city>Nocera Inferiore</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga-Medicina Interna 2</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Maddalena Casa di Cura di Alta Specialità Dipartimento Oncologico di III Livello</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti &quot;Villa Sofia-Cervello&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia Clinica - Azienda USL di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - Ospedale San Carlo</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliera &quot;Sant' Andrea&quot;-Università la Sapienza Seconda Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. di Ematologia e Trapianti - I.F.O. Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia - Ospedale S.Eugenio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore - Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia, Azienda Policlinico &quot;Umberto I&quot;, Università degli Studi &quot;La Sapienza&quot;</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Locale Viterbo - Polo Ospedaliero Centrale - Ospedale Di Ronciglione - U.O. di Ematologia</name>
      <address>
        <city>Ronciglione</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>S. G. Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia ed Ematologia S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia dell' Università degli Studi di Torino - &quot;Città della Salute e della Scienza di Torino&quot;</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, Meloni G, Ambrosetti A, Quarta G, Pagano L, Rege-Cambrin G, Elia L, Bertieri R, Annino L, Foà R, Baccarani M, Mandelli F. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007 May 1;109(9):3676-8. Epub 2007 Jan 9.</citation>
    <PMID>17213285</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>September 13, 2006</study_first_submitted>
  <study_first_submitted_qc>September 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2006</study_first_posted>
  <last_update_submitted>February 6, 2014</last_update_submitted>
  <last_update_submitted_qc>February 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Philadelphia positive</keyword>
  <keyword>Adult</keyword>
  <keyword>Elderly</keyword>
  <keyword>Imatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

